K. Cerchio

Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure¹

Johan Svensson, Lars Lönn, John‐Olov Jansson et al. · The Journal of Clinical Endocrinology & Metabolism · 1998 · 161 citations · Full text

Effect of L-000845704, an αVβ3 Integrin Antagonist, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporotic Women

M. Gail Murphy, K. Cerchio, S. Aubrey Stoch et al. · The Journal of Clinical Endocrinology & Metabolism · 2005 · 136 citations · Full text

Effect of Alendronate and MK-677 (a Growth Hormone Secretagogue), Individually and in Combination, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporotic Women¹

M. Gail Murphy, Michael R. McClung, Thomas J. Schnitzer et al. · The Journal of Clinical Endocrinology & Metabolism · 2001 · 79 citations

Oral Administration of Growth Hormone (GH) Releasing Peptide-Mimetic MK-677 Stimulates the GH/Insulin-Like Growth Factor-I Axis in Selected GH-Deficient Adults¹

Ian Chapman, Ora Hirsch Pescovitz, Gail Murphy et al. · The Journal of Clinical Endocrinology & Metabolism · 1997 · 63 citations · Full text

Oral Administration of the Growth Hormone Secretagogue MK-677 Increases Markers of Bone Turnover in Healthy and Functionally Impaired Elderly Adults

M. Gail Murphy, Mark A. Bach, D. Plotkin et al. · Journal of Bone and Mineral Research · 1999 · 48 citations · Full text

Bone Disease, Gh Secretagogue, Urology +14